Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cas

TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic

Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 2

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan

NEW YORK, June 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Ass

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale

Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Pri

MILWAUKEE, June 29, 2026 /PRNewswire/ -- Ademi LLP is investigating Theravance Biopharma (NASDAQ: TB

Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:

Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expandin

The Merger Agreement contains certain customary termination rights for the Company and Parent. Subje

Drugmaker ​Zymeworks ‌said ​on ​Monday ⁠it ​will ​buy ​Theravance ​Biopharma in ‌a $929 ⁠million ​de

Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarini

Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value

Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.10) per share which missed the a

B. Riley Securities analyst Mayank Mamtani maintains Theravance Biopharma (NASDAQ:TBPH) with a Ne

TD Cowen analyst Marc Frahm maintains Theravance Biopharma (NASDAQ:TBPH) with a Hold and raises t

BTIG analyst Julian Harrison reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintai

Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $1.15 per share which beat the ana

Top Wall Street analysts changed outlook on top names. Check all changes on analyst ratings page. Se

Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/down

HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a

B. Riley Securities analyst Mayank Mamtani downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy

Theravance Biopharma shares tumble after Phase 3 trial fails, company halts drug program and explore

US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vesse

BTIG analyst Julian Harrison maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and lowers t

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 900 points on Tues

HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a

BTIG analyst Julian Harrison reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintai

Oppenheimer analyst Trevor Allred initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a

BTIG analyst Julian Harrison maintains Theravance Biopharma (NASDAQ:TBPH) with a Buy and raises t

HC Wainwright & Co. analyst Douglas Tsao maintains Theravance Biopharma (NASDAQ:TBPH) with a

Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.07 per share which beat the ana

A retrospective cohort study of claims data demonstrated that following hospital discharge, patients

B. Riley Securities analyst Mayank Mamtani initiates coverage on Theravance Biopharma (NASDAQ:TBP

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH),